Enhanced Chemotherapy Regimen Shows Promise in Pancreatic Cancer Survival
Source-Inside-Precision-Medicine A recent study conducted by researchers at Yale Cancer Center (YCC) and Yale School of Medicine has unveiled promising results in the treatment of pancreatic cancer . Published in JAMA Oncology on June 20, the study focused on patients diagnosed with pancreatic ductal adenocarcinoma (PDAC), a particularly aggressive form of pancreatic cancer that accounts for the majority of cases. Known for its high mortality rate, PDAC is projected to become the second leading cause of cancer-related deaths in the United States by 2030. The research highlighted a modified chemotherapy approach that involved administering the treatment both before and after surgery. Traditionally, patients undergo surgery followed by chemotherapy. However, the study’s findings suggest that flipping this sequence—first administering chemotherapy and then proceeding with surgery—could lead to longer survival rates. This approach is especially pertinent for the 15 to 20% of pancreatic can...